Phase II Trial with Safety Run-in of MEK Inhibitor AS703026 in Subjects with Poor Prognosis Acute Myeloid Leukemia and Other Hematological Malignancies - AS703026 in Hematological Malignancies

Merck Serono S.A. - Geneva0 个研究点目标入组 0 人开始时间: 2009年4月9日最近更新: 2022年4月4日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Safety Run-in Part
•the subjects must fulfill all of the following criteria:
•1. Female and male subjects with one of the following conditions:
•a. Primary or secondary AML pathologically confirmed according to WHO classification, who meet at least one of the following conditions:
•i. Subjects with second or subsequent relapse after standard therapy, for whom no established treatment options are available,
•ii. Subjects refractory to available therapies, for example, who failed to achieve CR after 2 induction chemotherapy treatments,
•iii. Newly-diagnosed older subjects (=75 years of age), not candidates for intensive chemotherapy,
•b. Subjects with MDS, IPSS Int-2 or high risk who are resistant or intolerant to standard treatment and are not candidates for transplantation,
•c. Subjects with relapsed or refractory MM, who have failed or are intolerant to at least two prior therapies including thalidomide, lenalidomide and bortezomib,
•d. Subjects with advanced MPD for whom no established treatment options are available,
•e. Subjects with ALL, relapsed, refractory or intolerant to standard treatment and for whom no effective treatment options are available,
•2. Age =18 years,
•3. Subjects have read and understood the Informed Consent Form and are willing and able to give informed consent. They fully understand requirements of the trial and are willing to comply with all trial visits and assessments,
•4. Subjects and their partners must be willing to avoid pregnancy during the trial and until 1 month after the last trial drug administration. Males with female partners of childbearing potential and female subjects of childbearing potential must therefore be willing to use adequate contraception as approved by the Investigator, such as oral contraceptives, two barrier methods or one barrier method with spermicide or intrauterine device, 2 weeks before, during the trial and 1 month after. For the purposes of this trial, childbearing potential is defined as All female subjects after puberty unless they are post-menopausal for at least two years, surgically sterile or sexually inactive”.
•Phase II Part
•the subjects must fulfill all of the following criteria:
•1. Female and male subjects with newly diagnosed primary or secondary AML pathologically confirmed according to WHO classification, who have NOT been exposed to any prior therapy for AML with the exception of (a) emergency leukapheresis and (b) emergency treatment for hyperleukocytosis with hydroxyurea that is allowed until 24 hours before the start of the trial treatment. Note: Prior therapy for preexisting hematological condition e.g. MDS or MPD, including but not limited to hypomethylating agents is allowed until at least 2 weeks or 5 half lives of that agent before the first dose of AS703026.
•2. Subjects who meet at least one of the following conditions:
•a. Age =75 years
•b. Age =60 and < 75 years with at least one of the following poor prognostic factors:
•i. Secondary AML, as determined by known and documented exposure to leukemogenic therapy or environmental toxin,
•ii. antecedent history of MDS or myeloproliferative disorder according to WHO criteria for at least 3 months prior to trial entry, with prior bone marrow aspirate, biopsy and peripheral blood smear documenting the diagnosis,
•iii. At least one of the following unfavorable cytogenetic abnormalities: del(5q), –5, –7, del(7q), abn 3q, 9q, 11q, 20q, 21q, 17p, t(6;9), t(9;22) or complex karyotypes (= 3 unrelated abnormalities),

排除标准

•the subjects must NOT meet any of the following criteria:
•1. ECOG performance status 3 or greater,
•2. Hyperleukocytosis with > 30x109/L leukemic blasts in peripheral blood,
•3. Acute promyelocytic leukemia [t(15;17)],
•4. Administration of any antineoplastic therapy within at least 2 weeks or 5 half lives of that therapy of the first AS703026 dose; except the use of hydroxyurea as permitted in inclusion criteria,
•5. Participation in other clinical trials within at least 2 weeks of the first AS703026 dose,
•6. Clinical evidence of active CNS leukemia,
•7. Active and uncontrolled infection including but not limited to known infection with HIV, active hepatitis B, or hepatitis C. Subjects with an infection receiving treatment with antibiotics may be entered into the trial if they are afebrile and hemodynamically stable for 48 hours prior to trial entry,
•8. Major surgery within two weeks prior to trial entry,
•9. Liver function tests above the following limits at the screening: total bilirubin > 1.5 x ULN unless related to Gilbert’s syndrome or hemolysis, AST and/or ALT > 2.5 X ULN, or for subjects with liver involvement AST and/or ALT > 5 x ULN ,
•10. INR > 1.5 ULN unless on treatment with warfarin,
•11. For female subjects: pregnant or breast-feeding,
•12. History of difficulty swallowing, malabsorption or other chronic gastro-intestinal disease or conditions that may hamper compliance and/or absorption of the tested product,
•13. Has significant cardiac conduction abnormalities and/ or pacemaker,
•14. Has retinal degenerative disease (hereditary retinal degeneration or age-related macular degeneration), history of uveitis or history of retinal vein occlusion,
•15. Subjects with solid tumors, for whom the Investigator has clinical suspicion of active disease at the time of enrolment Patients with adequately treated early stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or cervical intraepithelial neoplasia (CIN) are eligible for this study,
•16. Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer(ed) from such,
•17. Other significant disease that in the Investigator’s opinion would exclude the subject from the trial,
•18. Legal incapacity or limited legal capacity.

研究者

发起方

Merck Serono S.A. - Geneva

相似试验

进行中（未招募）

不适用

Trial of gemcitabine with or without MSC1936369B in pancreas cancerFirst line treatment of metastatic pancreas CA with MSC1936369B in combination with gemcitabine and / or after progression under gemcitabine monotherapy second line treatment with MSC1936369B.MedDRA version: 17.0Level: LLTClassification code 10033576Term: Pancreas carcinomaSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10033577Term: Pancreas carcinoma recurrentSystem Organ Class: 100000004864

EUCTR2009-011992-61-DEMerck Serono S.A. - Geneva86

进行中（未招募）

不适用

EUCTR2009-011992-61-BEMerck Serono S.A. - Geneva86

进行中（未招募）

1 期

EUCTR2009-011992-61-GBMerck Serono S.A. - Geneva141

进行中（未招募）

1 期

Phase II randomized trial of MEK inhibitor AS703026 or placebo combined with gemcitabine in chemo-naïve metastatic pancreas cancer subjectsFirst line treatment of metastatic pancreas CA with AS703026 in combination with gemcitabine and / or after progression under gemcitabine monotherapy second line treatment with AS703026.MedDRA version: 9.1Level: LLTClassification code 10033576Term: Pancreas carcinomaMedDRA version: 9.1Level: LLTClassification code 10033577Term: Pancreas carcinoma recurrent

EUCTR2009-011992-61-FRMerck Serono S.A. - Geneva141

进行中（未招募）

1 期

A dose finding trial of PF-02341066 and Binimetinib in bowel cancerCancer. Solid tumours in the escalation phase and colorectal cancer in the expansion groups.MedDRA version: 20.0Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2014-000463-40-GBniversity of Oxford82